Menarini Stemline

Overview

Menarini Stemline, part of the Menarini Group, is a biopharmaceutical company based in New York City that specializes in developing and commercializing innovative oncology therapeutics. Founded in 2003 and acquired by Menarini in 2020, the company aims to address unmet needs in cancer treatment, leveraging Menarini's extensive global infrastructure.

The product portfolio includes ELZONRIS, a CD123-targeted therapy approved for treating blastic plasmacytoid dendritic cell neoplasm, and ORSERDU, an oral selective estrogen receptor degrader for advanced breast cancer. With a strong commitment to advancing cancer care through research and development, Menarini Stemline operates multiple R&D centers and conducts clinical trials to support its mission of enhancing personalized solutions for hematologic malignancies and solid tumors.

Basic Information

Contact Details

• Phone: +1 646-502-2310
• Website: stemline.com
• LinkedIn: linkedin.com/company/menarinistemline

Key Focus Areas & Initiatives

• Healthcare and biotechnology innovation
• Drug commercialization
• Oncology pipeline development
• FDA approval and regulatory processes
• Rare cancer therapies
• Personalized medicine and cancer treatment access
• Biopharmaceutical development
• Research and development of targeted therapies
• Advanced cancer therapeutics
• Clinical trials for hematologic malignancies and solid tumors
• Cancer patient care and outcomes
• Precision oncology and molecular targeting
• Immunotherapy in oncology
• Translational medicine
• Partnerships and collaborations in cancer research

Technologies Used

• AI
• Active Campaign
• Amazon AWS
• Gmail
• Google AdWords Conversion
• Google Apps
• Google Tag Manager
• Hubspot
• Microsoft Excel
• Microsoft Office
• Microsoft Office 365
• Mobile Friendly
• OneTrust
• Outlook
• Remote
• Salesforce CRM Analytics
• Veeva CTMS
• Woo Commerce
• WordPress.org
• reCAPTCHA

Affiliated Organizations & Regional Branches

• MENARINI Group